Novartis eyes year-end filing in US for Fabhalta in C3G
Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 gl
Newsletters and Deep Dive digital magazine
Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 gl
11-12 November 2024 in London, UK
Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running.
GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.
Editor's Picks
Newsletters and Deep Dive
digital magazine